ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Research Advances in the Pulmonary Carcinogenic Effects of Atmospheric Fine Particulate Matter Mediated by GPER].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the leading cause of cancer-related death worldwide. Fine particulate matter (PM2.5), classified as a group I human carcinogen, has been extensively linked to lung cancer development through epidemiological studies. The G protein-coupled estrogen receptor (GPER) can be activated and induce tumorigenesis by environmental pollutants, and it is significantly overexpressed in lung cancer tissues, highlighting its critical role in disease progression. Research indicates that environmental estrogen-like components and metal ions in PM2.5 can activate GPER, thereby regulating downstream signaling pathways such as mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT). This activation triggers inflammatory responses, oxidative stress, and ferroptosis, ultimately promoting tumor cell proliferation, apoptosis, migration, epithelial-mesenchymal transition, and remodeling of the tumor microenvironment. Collectively, these mechanisms drive the initiation and progression of lung cancer. In summary, GPER serves as a pivotal molecular hub connecting PM2.5 exposure to lung cancer pathogenesis, presenting a promising therapeutic target. Inhibitors targeting GPER may offer novel strategies for the prevention and treatment of lung cancer. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.